Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events

NCT07694414 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Immune-Related Adverse Events

Interventions

DRUG: Rituximab (RTX)

Sponsor

Inge Marie Svane